West Pharmaceutical Services Set for Growth After Solid Q3, BofA Securities Says

MT Newswires Live

Oct 24, 2025

West Pharmaceutical Services (WST) is poised for continued growth through 2026 as high value product demand and GLP-1 exposure drive stronger margins and earnings, BofA Securities said in a note Thursday.

The firm said the company delivered a strong Q3, with strengths in high-value components and elastomers used in GLP-1 drugs lifting revenue and margins.

BofA now models 2025 EPS guidance of $7.10, up from its prior forecast of $6.75, and raised its 2026 EPS guidance to $7.90 from $7.50.

The firm also said West Pharmaceutical's management did not push back on consensus 2026 estimates and noted potential upside to street expectations.

BofA reiterated a buy rating on the stock and raised its price target to $370 from $310.

Price: 304.22, Change: -3.03, Percent Change: -0.99

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2578459805"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578459805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578459805?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 23:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578459805","market":"fut","top_or_hot":-1,"title":"West Pharmaceutical Services Set for Growth After Solid Q3, BofA Securities Says","media":"MT Newswires Live","content":"<html><body><p> West Pharmaceutical Services (WST) is poised for continued growth through 2026 as high value product demand and GLP-1 exposure drive stronger margins and earnings, BofA Securities said in a note Thursday.</p><p>The firm said the company delivered a strong Q3, with strengths in high-value components and elastomers used in GLP-1 drugs lifting revenue and margins.</p><p>BofA now models 2025 EPS guidance of $7.10, up from its prior forecast of $6.75, and raised its 2026 EPS guidance to $7.90 from $7.50.</p><p>The firm also said West Pharmaceutical's management did not push back on consensus 2026 estimates and noted potential upside to street expectations.</p><p>BofA reiterated a buy rating on the stock and raised its price target to $370 from $310.</p><p>Price: 304.22, Change: -3.03, Percent Change: -0.99</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>West Pharmaceutical Services Set for Growth After Solid Q3, BofA Securities Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWest Pharmaceutical Services Set for Growth After Solid Q3, BofA Securities Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-24 23:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> West Pharmaceutical Services (WST) is poised for continued growth through 2026 as high value product demand and GLP-1 exposure drive stronger margins and earnings, BofA Securities said in a note Thursday.</p><p>The firm said the company delivered a strong Q3, with strengths in high-value components and elastomers used in GLP-1 drugs lifting revenue and margins.</p><p>BofA now models 2025 EPS guidance of $7.10, up from its prior forecast of $6.75, and raised its 2026 EPS guidance to $7.90 from $7.50.</p><p>The firm also said West Pharmaceutical's management did not push back on consensus 2026 estimates and noted potential upside to street expectations.</p><p>BofA reiterated a buy rating on the stock and raised its price target to $370 from $310.</p><p>Price: 304.22, Change: -3.03, Percent Change: -0.99</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WST","symbol_name":"West Pharmaceutical Services Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2578459805","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578459805","pubTimestamp":1761321427,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"West Pharmaceutical Services  is poised for continued growth through 2026 as high value product demand and GLP-1 exposure drive stronger margins and earnings, BofA Securities said in a note Thursday.The firm said the company delivered a strong Q3, with strengths in high-value components and elastomers used in GLP-1 drugs lifting revenue and margins.BofA now models 2025 EPS guidance of $7.10, up from its prior forecast of $6.75, and raised its 2026 EPS guidance to $7.90 from $7.50.The firm also said West Pharmaceutical's management did not push back on consensus 2026 estimates and noted potential upside to street expectations.BofA reiterated a buy rating on the stock and raised its price target to $370 from $310.Price: 304.22, Change: -3.03, Percent Change: -0.99","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WST":"West Pharmaceutical Services Inc","BK4121":"生命科学工具和服务","BK4504":"桥水持仓","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4567":"ESG概念","BK4588":"碎股","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"美国银行证券表示，West Pharmaceutical Services在第三季度稳健后将实现增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WST":1.5},"content_text":"West Pharmaceutical Services (WST) is poised for continued growth through 2026 as high value product demand and GLP-1 exposure drive stronger margins and earnings, BofA Securities said in a note Thursday.The firm said the company delivered a strong Q3, with strengths in high-value components and elastomers used in GLP-1 drugs lifting revenue and margins.BofA now models 2025 EPS guidance of $7.10, up from its prior forecast of $6.75, and raised its 2026 EPS guidance to $7.90 from $7.50.The firm also said West Pharmaceutical's management did not push back on consensus 2026 estimates and noted potential upside to street expectations.BofA reiterated a buy rating on the stock and raised its price target to $370 from $310.Price: 304.22, Change: -3.03, Percent Change: -0.99","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}